We're here to share this week's top stories in dermatology news. This week, the FDA confirmed heart and cancer risks with a new Janus kinase inhibitor. Plus a new Danish study suggests topical corticosteroids may be associated with increased risk for osteoporosis. Read these stories and more!
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz) MDEdge, February 5, 2021
The Food and Drug Administration has alerted the public to an increased risk of serious heart-related problems and cancer risk associated with the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR), based on early results from a safety clinical trial comparing tofacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA).
Monitor Bone Health With High-Dose Topical Corticosteroids MedPage Today, January 20, 2021
A new Danish study suggests potent topical corticosteroids were associated with increased risk for osteoporosis.
Masculinizing Hormone Therapy Tied to Acne in Transmen MedPage Today, January 20, 2021
Acne was a common occurrence after initiating masculinizing hormone therapy (MHT), researchers reported. In a retrospective analysis of nearly 1,000 transgender individuals who started MHT, prevalence of acne jumped from just 6.3% to 31.1% after an average therapy duration time of 3.4 years, according to Erica Dommasch, MD, MPH, of Beth Israel Deaconess Medical Center in Boston, and colleagues.
Microencapsulated formulation of benzoyl peroxide improves rosacea Healio, January 28, 2021
Patients experienced progressive improvement in rosacea after treatment with a benzoyl peroxide formulation, according to results from an extension of two phase 3 trials presented at Maui Derm for Dermatologists.
UV-Induced Mutations in Seemingly Normal Skin May Predict Skin Cancer Reuters, January 13, 2021
A novel technique called ultradeep sequencing revealed clonal mutations (CMs) induced by ultraviolet (UV) light exposure in seemingly normal skin samples.